Meetings to be held in Toronto on February 7 and in Montreal on February 8 hosted by Mizuho.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead announces FDA approves Trodelvy in pre-treated HR+/HER2- breast cancer
- Gilead price target raised to $80 from $69 at Baird
- Gilead price target raised to $112 from $111 at Piper Sandler
- Gilead raises quarterly dividend 2.7% to 75c per share
- Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73